Rituximab biosimilar evaluated by network meta-analysis
Chiumente M, Mengato D, Messori A.
Studi real world
The growing health care needs and the increase of new and expensive health care technologies are a challenge for the sustainability of health systems worldwide. Biosimilars can be one of the solutions to reduce costs of cancer treatment, retaining the same efficacy and safety of originator drugs. Our network meta-analysis focused on the efficacy of rituximab in AFL and aimed at comparing rituximab biosimilar CT-P10 (Truxima®) versus Mabthera/Rituxan (rituximab originator). Our network meta-analysis was based on the bayesian method proposed by the National Institute for Health and Care Excellence (NICE). Odds ratio (OR) for all pairwise comparisons was the output of the analysis, along with the ranking histogram and 95% credible intervals (CrIs). Since no significant heterogeneity was found in the clinical trials, the Bayesian statistics analysis was performed with a fixed effect model. The results of our meta-analysis confirm the efficacy of rituximab biosimilar in treating AFL. Interestingly, the biosimilar ranked first in 88% of the bayesian simulations. Using CT-P10 in patients with AFL has a critical clinical relevance as, at least in Europe, this is the first case in which a biosimilar has been proposed for a potentially curative indication in oncologic patients. The “total evidence” approach can provide useful information for overcoming some skepticism regarding biosimilars.
Link PubMed del paper